HUTCHMED (China) Limited (AIM:HCM)
205.00
+3.00 (1.49%)
Mar 6, 2026, 11:32 AM GMT
HUTCHMED (China) Revenue
In the year 2025, HUTCHMED (China) had annual revenue of $548.51M USD, down -12.96%. HUTCHMED (China) had revenue of $277.68M in the half year ending June 30, 2025, a decrease of -47.89%.
Revenue
$548.51M
Revenue Growth
-12.96%
P/S Ratio
4.26
Revenue / Employee
$308.15K
Employees
1,780
Market Cap
1.74B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 548.51M | -81.69M | -12.96% |
| Dec 31, 2024 | 630.20M | -207.80M | -24.80% |
| Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
| Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
| Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hikma Pharmaceuticals | 2.49B |
| Allergy Therapeutics | 55.04M |
| Animalcare Group | 81.07M |
| Shield Therapeutics | 30.29M |
| Haleon | 11.03B |
| Venture Life Group | 31.23M |
| ECO Animal Health Group | 85.81M |
| Provexis | 871.27K |
HUTCHMED (China) News
- 4 hours ago - Intended Retirement of Independent Non-executive Director and changes of composition of board committees - GlobeNewsWire
- 17 hours ago - HUTCHMED (China) Limited (HCM) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 23 hours ago - HUTCHMED (China) Limited 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 1 day ago - An Overview of HUTCHMED (China)'s Earnings - Benzinga
- 4 weeks ago - HUTCHMED to Announce 2025 Final Results - GlobeNewsWire
- 4 weeks ago - HUTCHMED (China) Ltd (HCM) Stock Price Down 3.53% on Feb 2 - GuruFocus
- 7 weeks ago - HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet - GlobeNewsWire
- 2 months ago - Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026 - Benzinga